Provided are an Agathobaculum sp. strain having prophylactic or therapeutic effects on degenerative brain diseases, and use thereof. Since the intestinal microorganism Agathobaculum butyriciproducens SR79 strain of the present invention may have effects of inhibiting neuroinflammation and effects of improving movement regulation and cognitive and memory functions in animal models with degenerative brain diseases such as Parkinson's disease and Alzheimer's disease, the strain may be effectively used in foods, medicines, or feeds for preventing or treating brain diseases including Alzheimer's disease, Parkinson's disease, mild cognitive impairment, etc., and therefore, it is very useful in the relevant industries.

Provided are an Agathobaculum sp. strain having prophylactic or therapeutic effects on degenerative brain diseases, and use thereof. Since the intestinal microorganism Agathobaculum butyriciproducens SR79 strain of the present invention may have effects of inhibiting neuroinflammation and effects of improving movement regulation and cognitive and memory functions in animal models with degenerative brain diseases such as Parkinson's disease and Alzheimer's disease, the strain may be effectively used in foods, medicines, or feeds for preventing or treating brain diseases including Alzheimer's disease, Parkinson's disease, mild cognitive impairment, etc., and therefore, it is very useful in the relevant industries.

The present invention relates to a novel probiotic composition for regulation of intestinal immunity and, more specifically, to a composition including Lactobacillus johnsonii, Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis as active ingredients for suppressing inflammation and/or preventing, ameliorating, or treating inflammatory bowel diseases.

The present disclosure provides a novel serine protease variant.

This invention relates to the development of products that are alternatives to antibiotics with medically important human therapeutic uses for livestock meat and protein production efficiency. These products will be used to replace antibiotics used to rapidly increase lean muscle mass with specific feed regimens. The present invention is for the identification of non-human antibiotic products to be used with different feed regimens for livestock growth and meat promotion that include prebiotic supplements and keystone species probiotics that produce the desired growth promotion phenotypic effects. The present invention includes the identification of enterotypes that can be used as targets for recapitulation by compounds that are screened to produce the desired phenotype.

This invention relates to the development of products that are alternatives to antibiotics with medically important human therapeutic uses for livestock meat and protein production efficiency. These products will be used to replace antibiotics used to rapidly increase lean muscle mass with specific feed regimens. The present invention is for the identification of non-human antibiotic products to be used with different feed regimens for livestock growth and meat promotion that include prebiotic supplements and keystone species probiotics that produce the desired growth promotion phenotypic effects. The present invention includes the identification of enterotypes that can be used as targets for recapitulation by compounds that are screened to produce the desired phenotype.

The present invention provides novel use of Bifidobacterium lactis BL-99 in suppression of intestinal inflammation. Bifidobacterium lactis BL-99 of the present invention has the deposit number CGMCC 15650. It was discovered in the present invention that the strain alone was highly efficacious at suppressing intestinal inflammation, reducing inflammatory factors IL-6 and/or TNF-α, promoting anti-inflammatory factor IL-10, and reducing the tissue damage of colitis.

The present invention provides novel use of Bifidobacterium lactis BL-99 in suppression of intestinal inflammation. Bifidobacterium lactis BL-99 of the present invention has the deposit number CGMCC 15650. It was discovered in the present invention that the strain alone was highly efficacious at suppressing intestinal inflammation, reducing inflammatory factors IL-6 and/or TNF-α, promoting anti-inflammatory factor IL-10, and reducing the tissue damage of colitis.

A synergistic combination of butyric-acid-producing prebiotics and probiotics, which is used in the fields of foods, dietary supplements and drugs. Specifically, a composition containing probiotics and prebiotics, a food, dietary supplement or pharmaceutical preparation including the composition, and the use of the composition for alleviating and improving a disease or a discomfort, or reducing the occurrence of a disease or a discomfort, wherein the disease or discomfort is related to insufficient butyric acid in the intestine, or to insufficient butyric-acid-producing microorganisms in the intestine. A method for promoting Bifidobacterium lactis HNO19 to produce butyric acid, the method including using a galactooligosaccharide and lactulose as carbon sources for the cultivation of Bifidobacterium lactis HNO19, wherein the weight ratio of the galactooligosaccharide to lactulose is 1:1 to 4:1.

A synergistic combination of butyric-acid-producing prebiotics and probiotics, which is used in the fields of foods, dietary supplements and drugs. Specifically, a composition containing probiotics and prebiotics, a food, dietary supplement or pharmaceutical preparation including the composition, and the use of the composition for alleviating and improving a disease or a discomfort, or reducing the occurrence of a disease or a discomfort, wherein the disease or discomfort is related to insufficient butyric acid in the intestine, or to insufficient butyric-acid-producing microorganisms in the intestine. A method for promoting Bifidobacterium lactis HNO19 to produce butyric acid, the method including using a galactooligosaccharide and lactulose as carbon sources for the cultivation of Bifidobacterium lactis HNO19, wherein the weight ratio of the galactooligosaccharide to lactulose is 1:1 to 4:1.